NEW DELHI (25 February 2026) — The Central Drugs Standard Control Organization (CDSCO), India’s apex drug regulatory body, has overhauled its protocols for granting testing permissions to significantly reduce the time required for new drug approvals. Under the newly modified norms, pharmaceutical companies can now begin laboratory testing immediately upon filing an application, bypassing the previously mandatory waiting period for detailed regulatory scrutiny.
Shift from Scrutiny to Instant Issuance
Previously, the CDSCO conducted a comprehensive examination of the detailed specifications and protocols submitted by an applicant before issuing a No Objection Certificate (NOC) for testing. This pre-approval phase often added several weeks or months to the development timeline.
The new circular mandates that the NOC for testing drug samples at designated national laboratories shall be issued “immediately upon receipt of applications” in the concerned division. This “deemed approval” approach shifts the burden of technical compliance to the post-testing phase, where the results and the methodology will be scrutinised alongside the test reports.
Designated National Testing Laboratories
The directive applies to testing at several of India’s premier designated laboratories, including:
- IPC, Ghaziabad: Indian Pharmacopoeia Commission.
- CDTL, Mumbai: Central Drug Testing Laboratory.
- CRI, Kasauli: Central Research Institute (Central Drugs Laboratory).
- NIB, Noida: National Institute of Biologicals.
Impact on the Pharmaceutical Industry
The move is being hailed by industry stakeholders as a major step toward enhancing “Ease of Doing Business” in the pharmaceutical sector. By allowing testing to run in parallel with the initial administrative review, the government expects:
- Reduced Lead Times: Faster transition from the laboratory phase to clinical trials and final market authorization.
- Operational Efficiency: Streamlined resource management for biotech and pharma firms waiting for regulatory “green lights.”
- Global Competitiveness: Aligning India’s regulatory speed with international standards to attract more R&D and clinical research investments.
Safeguards and Compliance
While the NOC is now issued instantly, the CDSCO clarified that this does not imply a relaxation of quality standards. The technical scrutiny that previously occurred before the NOC will now be integrated into the final evaluation of the test results. If the subsequent review finds discrepancies in the initial application or testing protocols, the regulator reserves the right to reject the data or the drug application entirely.
Sources
- Central Drugs Standard Control Organization (CDSCO): Official Circular No. 12-01/2026-DC (25 February 2026)
- Press Trust of India (PTI): “CDSCO modifies norms for testing permissions to speed up drug approvals” (25 February 2026)
- The Economic Times: “Govt speeds up drug approvals; NOC for testing to be issued immediately” (26 February 2026)
- Business Standard: “India overhauls drug testing norms to cut regulatory delays” (26 February 2026)
Leave a Reply